DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Analyst / Instituional Investor Meetings29-02-2024
29-02-2024
DR.REDDY'S LABORATORIES LTD. - 500124 - Disclosure Under Regulation 30 Of The SEBI LODR Regulations, 2015
Disclosure under Regulation 30 of the SEBI Listing Regulations, 201528-02-2024
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Analyst / Institutional Investor Meetings26-02-2024
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of equity shares on exercise of stock options under Employee Stock Options Scheme22-02-2024
Dr. Reddy's Labs - U.S., Europe To Drive Growth: Nirmal Bang
The US market has demonstrated growth in both base business as well as limited volume launches such as Lenalidomide (Revlimid).22-02-2024
DR.REDDY'S LABORATORIES LTD. - 500124 - Disclosure Under Regulation 30 Of SEBI LODR
Disclosure under Regulation 30 of SEBI LODR21-02-2024
What Dr. Reddy's Stands To Gain From Buying Novartis' India Business
Novartis India's brands could complement Dr Reddy's existing presence in those segments, according to Nomura.19-02-2024
DR.REDDY'S LABORATORIES LTD. - 500124 - Clarification On Reported News Article
Clarification on reported news article17-02-2024
DR.REDDY'S LABORATORIES LTD. - 500124 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of share certificates16-02-2024
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copies of newspaper advertisement16-02-2024